Company Overview and News

48
EU mergers and takeovers (Sept 21)

11h reuters - 1
BRUSSELS, Sept 21 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CVG 4091 FOX RIO RIO XOM SPR CG IX DTEGF SNX RTPPF BKNG RIO RTNTF MSFT HPQ FOXA DTEGY DIS

47
EU mergers and takeovers (Sept 20)

2018-09-20 reuters
BRUSSELS, Sept 20 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CVG 4091 FOX RIO RIO XOM SPR CG IX DTEGF SNX RTPPF BKNG RIO RTNTF MSFT HPQ FOXA DTEGY DIS

3
Samsung Electronics: A Long-Term Buy

2018-09-20 seekingalpha
The company carries a lot of excess cash on the balance sheet (partially being returned to shareholders).
SSNNF SSNLF AAPL BC94 VZ SMSN DTEGF DTEGY SMSD

 
Austria's telecoms regulator gives go-ahead for 5G auction

2018-09-19 reuters
VIENNA, Sept 19 (Reuters) - Austria’s telecoms regulator gave mobile operators until November to apply to take part in a 5G frequency auction scheduled to start next February.
DTEGF DTEGY

47
EU mergers and takeovers (Sept 18)

2018-09-18 reuters
BRUSSELS, Sept 18 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CVG 4091 FOX RIO RIO XOM SPR CG IX DTEGF SNX RTPPF RIO RTNTF MSFT HPQ FOXA DTEGY DIS

44
EU mergers and takeovers (Sept 17)

2018-09-17 reuters
BRUSSELS, Sept 17 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CVG 4091 FOX RIO RIO XOM CG IX DTEGF SNX RTPPF RIO RTNTF MSFT FOXA DTEGY DIS

25
EU mergers and takeovers (Sept 14)

2018-09-14 reuters
BRUSSELS, Sept 14 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CVG 4091 RIO RIO XOM CG IX DTEGF SNX RTPPF RIO RTNTF DTEGY

40
EU mergers and takeovers (Sept 13)

2018-09-13 reuters
BRUSSELS, Sept 13 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CVG 4091 GEC GE RIO RIO XOM CG IX DTEGF SNX RTPPF RIO RTNTF GNE DTEGY

 
Deutsche Telekom says EU raises concerns over Tele2's Dutch deal

2018-09-13 channelnewsasia
Deutsche Telekom said on Thursday that the European Commission had raised competition concerns about the effect of its planned purchase of the Dutch operations of Sweden's Tele2 on the mobile retail market.
DTEGF DTEGY

 
Thyssen interim CEO plans shake-up of engineering unit: source

2018-09-12 reuters
FRANKFURT/DUESSELDORF (Reuters) - Thyssenkrupp’s (TKAG.DE) interim boss Guido Kerkhoff is working on a restructuring of the German conglomerate’s plant engineering and shipbuilding division, a source familiar with the matter said on Wednesday.
DTEGF DTEGY

39
EU mergers and takeovers (Sept 12)

2018-09-12 reuters
BRUSSELS, Sept 12 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CVG 4091 GEC GE RIO RIO XOM IX DTEGF SNX RTPPF RIO RTNTF GNE DTEGY

39
EU mergers and takeovers (Sept 11)

2018-09-11 reuters
BRUSSELS, Sept 11 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CVG GEC GE RIO RIO XOM IX DTEGF SNX RTPPF RIO RTNTF GNE DTEGY

 
Telecom Italia - Undervalued Shares With A Catalyst

2018-09-10 seekingalpha
Paul Singer's Elliott Management has wrested control of Telecom Italia's Board from Vivendi (controlled by Bolloré Group) and is pushing hard to unlock shareholder value.
TI DTEGF DTEGY

18
EU mergers and takeovers (Sept 7)

2018-09-07 reuters
BRUSSELS, Sept 7 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
RTPPF GEC GE RIO RIO RIO RTNTF GNE IX DTEGF DTEGY

18
EU mergers and takeovers (Sept 6)

2018-09-06 reuters
BRUSSELS, Sept 6 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
RTPPF GEC GE RIO RIO RIO RTNTF GNE IX DTEGF DTEGY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 251566105